Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse
Validation Efforts Stalled Again
The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.
You may also be interested in...
With a PRIME designation also in hand for isaralgagene civaparvovec, Sangamo still needs to secure a partner before beginning its pivotal trial, which importantly will not have to include a head-to-head comparison with enzyme replacement therapies.
The US group has had a tough year but the signs look more promising for isaralgagene civaparvovec as the FDA agrees on the design for a registrational trial for the gene therapy. Now Sangamo needs to secure a partner.
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.